Skip to main content

Cencora, Inc. guidance

  • COR · NYSE
  • Distribution
  • Health Care Distributors
  • S&P 500
$356.94−0.58%Close 16 Nov 2026 · Market value $67.23B

In its results release of 4 Nov 2026 (Q4 FY2026), Cencora, Inc. gave 2 forecasts in figures, among them EPS (adjusted) of $19.40 to $19.75 for FY2027.

Read from the company's earnings releases and outlook updates of the last two years. Each forecast is shown with the sentence or table row it was read from; what a release does not state in figures is not shown.

Latest guidance given with Q4 FY2026 results, 4 Nov 2026

MeasurePeriodGuidanceAs stated
EPS · AdjustedFY2027$19.40 to $19.75Fiscal 2027 Adjusted Diluted EPS Expected to be in the Range of $19.40 to $19.75, reflecting growth of 8 percent to 10 percent
EPS growth · Adjusted · ReaffirmedFY2027+10% to +14%The Company is reaffirming its long-term growth target that contemplates adjusted operating income growth of 7% to 10% and adjusted diluted EPS growth of 10% to 14%.

Source: the company's earnings release.

Guidance against results above 1 · within 0 · below 0

The last range given before each period closed, how it moved between releases, and the figure then filed. A measure the company defines itself, or one not comparable with the filed figure, has no verdict.

MeasurePeriodLast guidanceRevisionsDeliveredResult
EPS · AdjustedFY2027$19.40 to $19.75Given once—To come
EPS growth · AdjustedFY2027+10% to +14%Given once—To come
EPS · AdjustedFY2026$17.75 to $17.95Raised 3 times—To come
Free cash flow · AdjustedFY2026$3.00BUnchanged—To come
Capital expendituresFY2026$900MUnchanged—To come
Tax rate · AdjustedFY202620%Lowered once—To come
Revenue growthFY2025About +9%Raised once+9.31%Within the range
Capital expendituresFY2025About $600MGiven once$668MAbove the range

COR in the terminal

Guidance said on earnings calls, every revision charted, and guidance set against the analysts' consensus.